吉非替尼靶向治疗晚期肺腺癌的临床研究  

Clinical Study of Advanced Lung Cancer Targeted Therapy Gefitinib

作　　者：王书霞[1] 周文华[1] 

机构地区：[1]三明市第一医院肿瘤内科,福建三明365001

出　　处：《中外医疗》2016年第30期133-135,共3页China & Foreign Medical Treatment

摘　　要：目的探析吉非替尼靶向治疗晚期肺腺癌的临床效果。方法方便选择2011年6月—2016年6月期间在该院接受医治的68例晚期肺腺癌患者为观察对象。所选患者均采取吉非替尼进行医治。观察治疗后不良反应、缓解时间、肿瘤进展时间以及总生存期、1年生存率以及影响疗效相关因素。结果在该组68例患者中,完全缓解率4.41%、部分缓解率39.71%、稳定率47.06%,疾病控制率91.18%。平均缓解时间为（8.2±1.6）个月,平均进展时间为（4.8±1.2）个月,平均生存期（12.1±3.6）个月,1年生存率47.06%。应用吉非替尼后,EGFR基因突变的肺腺癌患者有效率为71.43%,显著高于基因状态不明的肺腺癌患者（31.91%）,χ^29.68,P〈0.01,经比较差异有统计学意义。结论对晚期肺腺癌患者开展吉非替尼靶向治疗具有有效率高,疗效显著、不良反应小、安全性高等优势,值得临床推广应用。Objective Analysis of gefitinib targeted therapy of advanced lung cancer clinical results. Methods Convenient selection from June 2011 to June 2016 in our hospital during the treatment 68 patients with advanced lung cancer patients observed object. The selected patients were taking gefitinib treatment.observed adverse reactions after treatment, duration of remission, time to tumor progression, and overall survival, 1 year survival rate and the effect of related factors. Results In the group of 68 patients, complete remission rate of 4.41%, partial remission rate was 39.71%, stable rate 47.06%, disease control rate of 91.18%. The average remission time（8.2±1.6）months, the median time to progression for（4.8 ±1.2） months,the mean survival period（12.1± 3.6） months and 1 year survival rate 47.06%. Ji non imatinib after, EGFR mutations in lung adenocarcinoma patients with efficiency 7 1.43%, significantly higher than the status of the unknown gene in patients with lung adenocarcinoma（31.91%）,χ^29.68, P〈0.01, the comparison showed significant difference. Conclusion Patients with advanced lung adenocarcinoma carried gefitinib targeted therapy with a high efficiency, a significant effect, toxic side effects, safe and other advantages, is worthy of clinical application.

关 键 词：吉非替尼 靶向治疗 晚期肺腺癌 

分 类 号：R734[医药卫生—肿瘤]